Liquid biopsy epigenomic profiling for cancer subtypingSylvan C. Baca, Matthew L. Freedman, Ji-Heui Seo et al.|Nature Medicine|2023Cited by 119
Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Ann H. Partridge et al.|Clinical Cancer Research|2024Cited by 43
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Rachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Journal of Clinical Oncology|2024Cited by 6
Author Correction: Liquid biopsy epigenomic profiling for cancer subtypingSylvan C. Baca, Matthew L. Freedman, Ji-Heui Seo et al.|Nature Medicine|2023Cited by 1
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Sheng Sun et al.|Unknown|2024Cited by 1